Iron infusion with certain formulations, such as ferric carboxymaltose, causes FGF23-mediated hypophosphatemia by reducing FGF23 cleavage to a greater extent than reducing FGF23 transcription. The gene discussed is FGF23; the disease is hypophosphatemia.